Rapid size dependent deletion of foreign gene sequences inserted into attenuateted HIV-1 upon infection in vivo: Implications for vaccine development

Current HIV Research

Volumn 3, Issue 4, 2005, Pages 377-392

  Brooks, David G ^a,d   Cohen, Michael D ^a   Jamieson, Beth D ^b   Poon, Betty ^b   Kitchen, Scott G ^b   Chow, Samson A ^a   Chen, Irvin S Y ^a,b   Zack, Jerome A ^a,b   Koka, Prasad S ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Attenuation; Excision; HIV; Reporter; SCID hu

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; THYMIDINE KINASE; VPR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; FETUS; GENE DELETION; GENE INSERTION; GENE SEQUENCE; GENE TARGETING; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REPORTER GENE; REVIEW; SCID MOUSE; SUICIDE GENE; VACCINE PRODUCTION; VIRAL GENETICS; VIRUS LOAD; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; ANTIGENS, CD24; ANTIGENS, THY-1; BLOTTING, WESTERN; GENES, NEF; GENES, REPORTER; GENES, VPR; GREEN FLUORESCENT PROTEINS; HIV INFECTIONS; HIV-1; MICE; MICE, SCID; SEQUENCE DELETION; THYMIDINE KINASE; VACCINES, ATTENUATED; VIRUS REPLICATION;

EID: 27844569435     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016205774370410     Document Type: Review

References (52)

1. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. (1986). Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. Journal of Virology. 59: 284-291.
2. Aldrovandi GM, Feuer G, Gao L, Jamieson B, Kristeva M, Chen ISY, Zack JA. (1993). The SCID-hu mouse as a model for HIV-1 infection. Nature. 363:732-7336.
3. Aldrovandi GM, Zack JA. (1996). Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. Journal of Virology. 70: 1505-1511.
4. Alexander L, Veazey RS, Czajak S, DeMaria M, Rosenzweig M, Lackner AA, Desrosiers RC, Sasseville VG. (1999). Recombinant simian immunodeficiency virus expressing green fluorescent protein identifies infected cells in rhesus monkeys. AIDS Research and Human Retroviruses. 15: 11-21.
5. Alexander L, Weiskopf E, Greenough TC, Gaddis NC, Auerbach MR, Malim MH, O'Brien SJ, Walker BD, Sullivan JL, and Desrosiers RC. (2000). Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. Journal of Virology. 74: 4361-4376.
6. An DS, Morizono K, Li Q-X, Mao SH, Lu S, and Chen ISY. (1999). An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. Journal of Virology. 73: 7671-7677.
7. Anderson JL, Hope TJ. (2003). Recent insights into HIV accessory proteins. Current Infectious Disease Reports. 5: 439-450.
8. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM. (1995). Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science. 267: 1820-1825.
9. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson R, Greene MF, McClure HM, Martin UN, Ruprecht RM. (1999). Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nature Medicine. 5: 194-203.
10. Bonyhadi ML, Rabin L, Salimi S, Brown DA, Kosek J, McCune JM, Kaneshima H. (1993). HIV induces thymus depletion in vivo. Nature. 363:728-732.
11. Bour S, Strebel K. (2003). The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes and Infection. 5: 1029-1039.
12. Chi J-T, Chang HY, Wang NH, Chang DS, Dunphy N, Brown PO. (2003). Genomewide view of gene silencing by small interfering RNAs. Proceedings of National Academy of Sciences USA. 100: 6343-6346.
13. Chtarto A, Tenenbaum L, Velu T, Brotchi J, Levivier M, Blum D. (2003). Minocycline-induced activation of tetracycline-responsive promoter. Neuroscience Letters. 352: 155-158.
14. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. (1998). HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature. 391: 397-401
15. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. (1992). Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 258: 1938-1941.
16. Das AT, Zhou X, Vink M, Klaver B, Verhoef K, Mqarzio G, Berkhout B. (2004). Viral evolution as a tool to improve the tetracycline-regulated gene expression system. Journal of Biological Chemistry. 279: 18776-18782.
17. Desrosiers RC. (1999). Strategies used by human immunodeficiency virus that allow persistent viral replication. Nature Medicine. 5: 723-725.
18. Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AY, Arthur LO, Johnson RP. (1998). Identification of highly attenuated mutants of simian immunodeficiency virus. Journal of Virology. 72: 1431-1437.
19. Dillin A. (2003). The specifics of small interfering RNA specificity. Proceedings of National Academy of Sciences USA. 100: 6289-6291.
20. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, Cullen C, Evans DT, Desrosiers RC, Mothe BR, Sidney J, Sette A, Kunstman K, Wolinsky S, Piatak M, Lifson J, Hughes AL, Wilson N, O'Connor DH, Watkins DI. (2004). Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nature Medicine. 10: 275-281.
21. Gambhir SS, Bauer E, Black ME, Liang Q, Kokoris MS, Barrio JR, Iyer M, Namavari M, Phelps ME, Herschman HR. (2000). A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proceedings of National Academy of Sciences USA. 97: 2785-2790.
22. Gibbs JS, Regier DA, Desrosiers RC. (1994). Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Research and Human Retroviruses. 10: 333-342.
23. Greenough TC, Sullivan JL, Desrosiers RC. (1999). Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. New England Journal of Medicine. 340: 236-237.
24. Jamieson BD, Aldrovandi GM, Planelles V, Jowett JMB, Gao L, Bloch LM, Chen ISY, Zack JA. (1994). Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. Journal of Virology. 68: 3478-3485.
25. Jamieson BD, Zack JA. (1998). In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus. Journal of Virology. 72: 6520-6526.
26. Javaherian K, Langlois AJ, Schmidt S, Kaufmann M, Cates N, Langedijk JP, Meloen RH, Desrosiers RC, Burns DP, Bolognesi DP. (1992). The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proceedings of National Academy of Sciences USA. 89: 1418-1422.
27. Ji Y, Marra A, Rosenberg M, Woodnutt G. (1999). Regulated antisense RNA eliminates alpha-toxin virulence in Staphylococcus aureus infection. Journal of Bacteriology. 181: 6585-6590.
28. Jowett JBM, Planelles V, Poon B, Shah NP, Chen M-L, Chen ISY. (1995). The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2+M phase of the cell cycle. Journal of Virology. 69: 6304-6313.
29. Kaneshima H, Su L, Bonyhadi ML, Connor RI, Ho DD, McCune JM. (1994). Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse. Journal of Virology. 68: 8188-8192.
30. Koka PS, Brooks DG, Razai, A, Kitchen CM, Zack JA. (2003). HIV-1 infection alters cytokine mRNA expression in the thymus. AIDS Research and Human Retroviruses. 19: 1-12.
31. Koka P S, Fraser JK, Bryson Y, Bristol GC, Aldrovandi GM, Daar ES, Zack JA. (1998). Human immunodeficiency virus inhibits multilineage hematopoiesis in vivo. Journal of Virology. 72:5121-5127.
32. Koka PS, Jamieson BD, Brooks DG, Zack JA. (1999). Human immunodeficiency virus type 1-induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. Journal of Virology. 73:9089-9097.
33. Koka PS, Kitchen CM, Reddy ST. (2004). Targeting c-Mpl for revival of human immunodeficiency virus type 1-induced hematopoietic inhibition when CD34+ progenitor cells are re-engrafted into a fresh stromal microenvironment in vivo. Journal of Virology. 78: 11385-11392.
34. Kollmann TR, Kim A, Peettoello-Mantovani M, Hachamovitch M, Rubinstein A, Goldstein M, Goldstein H. (1995). Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice. Journal of Immunology. 154: 908-921.
35. Lottmann H, Vanselow J, Hessabi B, Walther R. (2001). The Tet-On system in transgenic mice: inhibition of the mouse pdx-1 gene activity by antisense RNA expression in pancreatic beta-cells. Journal of Molecular Medicine. 79: 321-328.
36. Mariani R, Kirchhoff F, Greenough TC, Sullivan JL, Desrosiers RC, Skowronski J. (1996). High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. Journal of Virology. 70: 7752-7764.
37. Marzio G, Verhoef K, Vink M, Berkhout B. (2001). In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proceedings of National Academy of Sciences USA. 98: 6342-6347.
38. McCune JM, Namikawa R, Kaneshima H, Schultz LD, Lieberman M, Weissman IL. (1988). The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function. Science. 241:1632-1639.
39. Montefiori DC, Baba TW, Li A, Bilska M, Ruprecht RM. (1996). Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. Journal of Immunology. 157: 5528-5535.
40. Nathanson N, Mathieson BJ. (2000). Biological considerations in the development of a human immunodeficiency virus vaccine. Journal of Infectious Diseases. 183: 579-589.
41. Ohkawa J, Taira K. (2000). Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter. Human Gene Therapy. 11: 577-585.
42. Pantuck AJ, Matherly J, Zisman A, Nguyen D, Berger F, Gambhir SS, Black ME, Belldegrun A, Wu L. (2002). Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Human Gene Therapy. 13: 777-789.
43. Planelles V, Haislip A, Withers-Ward ES, Stewart SA, Xie Y, Shah NP, Chen ISY. (1995). A new reporter system for detection of viral infection. Gene Therapy. 2: 369-376.
44. Quinto I, Mallardo M, Baldassarre F, Scala G, Englund G, Jeang K-T. (1999). Potent and stable attenuation of live-HIV-1 by gain of a proteolysis-resistant inhibitor on NF-κB (IκB-αS32 /36A) and the implications for vaccine development. Journal of Biological Chemistry. 274: 17567-17572.
45. Shibata R, Siemon C, Czajak SC, Desrosiers RC, Martin MA. (1997). Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. Journal of Virology. 71: 8141-8148.
46. Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD. (1994). The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. Journal of Experimental Medicine. 179: 115-123.
47. Stanley S K, McCune JM, Kaneshima H, Justement JS, Sullivan M, Boone E, Baseler M, Adelsberger J, Bonyhadi M, Orenstein J, Fox CH, Fauci AS. (1993). Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. Journal of Experimental Medicine. 178: 1151-1163.
48. Stopak K, de Noronha C, Yonemoto W, Greene WC. (2003). HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Molecular Cell. 12: 591-601.
49. Terwilliger EF, Godin B, Sodroski JG, Haseltine WA. (1989). Construction and use of a replication-competent human immunodeficiency virus (HIV-1) that expresses the chloramphenicol acetyltransferase enzyme. Proceedings of National Academy of Sciences USA. 86: 3857-3861.
50. Verhoef K, Marzio G, Hillen W, Bujard H, Berkhout B. (2001). Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat. Journal of Virology. 75: 979-987.
51. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC. (1996). Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. Journal of Virology. 70: 3724-3733.
52. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen ISY. (1990). HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 61: 213-222.